Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2010 1
2011 1
2013 2
2014 1
2015 2
2017 2
2018 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Cerebrospinal fluid rhinorrhea: diagnosis and management.
Kerr JT, Chu FW, Bayles SW. Kerr JT, et al. Among authors: chu fw. Otolaryngol Clin North Am. 2005 Aug;38(4):597-611. doi: 10.1016/j.otc.2005.03.011. Otolaryngol Clin North Am. 2005. PMID: 16005720 Review.
Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens.
DeFalco J, Harbell M, Manning-Bog A, Baia G, Scholz A, Millare B, Sumi M, Zhang D, Chu F, Dowd C, Zuno-Mitchell P, Kim D, Leung Y, Jiang S, Tang X, Williamson KS, Chen X, Carroll SM, Espiritu Santo G, Haaser N, Nguyen N, Giladi E, Minor D, Tan YC, Sokolove JB, Steinman L, Serafini TA, Cavet G, Greenberg NM, Glanville J, Volkmuth W, Emerling DE, Robinson WH. DeFalco J, et al. Among authors: chu f. Clin Immunol. 2018 Feb;187:37-45. doi: 10.1016/j.clim.2017.10.002. Epub 2017 Oct 12. Clin Immunol. 2018. PMID: 29031828 Free article.
Ubiquitin ligase COP1 coordinates transcriptional programs that control cell type specification in the developing mouse brain.
Newton K, Dugger DL, Sengupta-Ghosh A, Ferrando RE, Chu F, Tao J, Lam W, Haller S, Chan S, Sa S, Dunlap D, Eastham-Anderson J, Ngu H, Hung J, French DM, Webster JD, Bolon B, Liu J, Reja R, Kummerfeld S, Chen YJ, Modrusan Z, Lewcock JW, Dixit VM. Newton K, et al. Among authors: chu f. Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):11244-11249. doi: 10.1073/pnas.1805033115. Epub 2018 Oct 15. Proc Natl Acad Sci U S A. 2018. PMID: 30322923 Free PMC article.
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA, LoRusso PM. Eder JP, et al. Among authors: chu f. Clin Cancer Res. 2010 Jul 1;16(13):3507-16. doi: 10.1158/1078-0432.CCR-10-0574. Epub 2010 May 14. Clin Cancer Res. 2010. PMID: 20472683 Clinical Trial.
Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG.
Wang X, Quarmby V, Ng C, Chuntharapai A, Shek T, Eigenbrot C, Kelley RF, Shia S, McCutcheon K, Lowe J, Leddy C, Coachman K, Cain G, Chu F, Hotzel I, Maia M, Wakshull E, Yang J. Wang X, et al. Among authors: chu f. MAbs. 2013 Jul-Aug;5(4):540-54. doi: 10.4161/mabs.24822. Epub 2013 Apr 29. MAbs. 2013. PMID: 23774668 Free PMC article.
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Yu P, Laird AD, Du X, Wu J, Won KA, Yamaguchi K, Hsu PP, Qian F, Jaeger CT, Zhang W, Buhr CA, Shen P, Abulafia W, Chen J, Young J, Plonowski A, Yakes FM, Chu F, Lee M, Bentzien F, Lam ST, Dale S, Matthews DJ, Lamb P, Foster P. Yu P, et al. Among authors: chu f. Mol Cancer Ther. 2014 May;13(5):1078-91. doi: 10.1158/1535-7163.MCT-13-0709. Epub 2014 Mar 14. Mol Cancer Ther. 2014. PMID: 24634413
13 results